Navigation Links
Hyperion Therapeutics Elects Lota Zoth to Board of Directors
Date:4/7/2008

SOUTH SAN FRANCISCO, Calif., April 7, 2008 /PRNewswire/ -- Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S. Zoth has been elected to the company's Board of Directors. Ms. Zoth formerly served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. with oversight of finance, information technology and public affairs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

In discussing her appointment, Ms. Zoth commented, "Hyperion's co-promotion agreements and strong product pipeline make it a very attractive opportunity. I look forward to helping the Hyperion team continue to execute on its growth objectives."

Prior to MedImmune, Ms. Zoth was Chief Accounting Officer for PSINet, Inc. and Sodexho Marriott Services, Inc., both of which were publicly-held companies. She also served in various finance executive roles at Marriott International and PepsiCo, Inc. after spending almost a decade at Ernst & Young as an audit executive. Ms. Zoth is a certified public accountant and holds a bachelor's of business administration degree in accounting from Texas Tech University.

"Lota's extensive financial and operational background will be a valuable addition to our Board of Directors," said Chris Rivera, President and Chief Executive Officer of Hyperion Therapeutics, Inc. "We look forward to her contributions as we build out our financing strategies with an eye towards accessing the public markets."

About Hyperion Therapeutics

Hyperion Therapeutics is a fully-integrated specialty therapeutics company committed to becoming a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs. Hyperion's commercial operations division currently markets two products in the United States for urea cycle disorder. The Company is also conducting two phase II trials, one in the chronic treatment of urea cycle disorder and the other in the treatment of acute hepatic encephalopathy. Hyperion is headquartered in South San Francisco, CA. For additional information, visit http://www.hyperiontx.com.


'/>"/>
SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3. Antisense therapeutics scientist out to pull more big deals
4. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
5. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
6. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
9. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
10. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... wear distributors and International relief organizations across the globe to provide effective protection ... lifestyle and work wear collections via insectshield.com . In the wake of ...
(Date:4/23/2017)... ... 2017 , ... Altura Communication Solutions, a nationwide provider of ... and SMB specialization. Altura is now qualified to sell, install and support ... Certification, Altura fulfilled the training and exam requirements for the Cisco Small Medium ...
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer ... President of Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is ... development, and strategic planning for the company. Recognized industry-wide as a healthcare ...
(Date:4/21/2017)... ... April 21, 2017 , ... The staff at Palm Beach Face is proud to announce that ... 2017 London Marathon. Set to take place on April 23rd, the London Marathon has a ... will run as part of team EMPOWER, raising money for the international charity, Smile Train. ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: